Novel Bispecific Antibody Active in Recurrent/Metastatic Head and Neck Cancer Responses in 37% of patients previously treated with anti-PD-1/L1 agents, platinum chemotherapy Apr 18, 2023
Responses to PD-1 Blockade Approach 90% in Rare Melanoma "One of the highest tumor response rates we've seen in any cancer," study discussant says Apr 17, 2023
Including Anti-PD-1 in First-Line Ups Survival in Biliary Tract Cancer Another option for difficult-to-treat disease Apr 17, 2023
'Potential' New Option for Operable NSCLC Adding perioperative durvalumab to neoadjuvant chemo improved pCR rates, event-free survival Apr 17, 2023
Adjuvant Combo May Change Practice in High-Risk Liver Cancer Atezolizumab-bevacizumab reduced the risk of recurrence by about 30% Apr 17, 2023
Personalized Cancer Vaccine Boosts Recurrence-Free Survival in Melanoma Clinical implications apply to virtually all solid tumors and possibly hematologic malignancies Apr 17, 2023
Intratumoral Combo Shrinks Melanomas Refractory to Anti-PD-1 But response rate driven primarily by injected lesions, expert points out Apr 14, 2022
Anti-CD39 Combination Therapy Promising in Gastric/GEJ Cancer Responses in a majority of patients, evidence of durability with TTX-030, chemoimmunotherapy Apr 14, 2022
Dual Immunotherapy Improves PFS in Melanoma Resistant to Anti-PD-1 Six-month PFS rate more than doubled with nivolumab/ipilimumab versus ipilimumab alone Apr 13, 2022
Boosting Responses to Neoadjuvant Therapy in Resectable NSCLC Multi-drug platform study identifies promising durvalumab-based combinations Apr 12, 2022
Neoadjuvant Nivolumab a 'New Standard' in Lung Cancer "Another quantum leap in lung cancer therapy," expert says Apr 12, 2022
Genetic Score Shows Promise for Honing PSA Precision Fewer unnecessary biopsies projected with use of genetics-adjusted values Apr 12, 2022
PARP Inhibitor-Based Triplet Promising in Endometrial Cancer Olaparib/cyclophosphamide/metformin combo appears effective in older, heavily pretreated patients Apr 11, 2022
Longer-Term Sotorasib Data 'Encouraging' in KRAS-Mutated NSCLC Prolonged tumor response seen in 2-year analysis Apr 11, 2022
DCIS Recurrence Often Represents a New Primary Breast Cancer Almost a fifth of cases unrelated to primary DCIS, raising questions about current treatment Apr 11, 2022
Bispecific Antibody-NK Cell Complex Impresses in Early Hodgkin/NHL Trial Objective responses in 89% of patients with no CRS, neurotoxicity, or graft-versus-host disease Apr 11, 2022
RET Fusion Inhibitor Active Beyond Lung, Thyroid Cancers Responses to selpercatinib in almost half of tumors outside approved indications May 21, 2021
New Anti-PD1 Drugs Boost Survival in Treated Lung Cancer Questions about generalizability of results with China-developed therapies Apr 14, 2021
Targeted Drug Yields Durable Responses in Rare Blood Neoplasm Most advanced systemic mastocytosis patients responded to KIT D816V inhibitor Apr 13, 2021
Another FGFR Inhibitor Active in Bile Duct Cancers Clinical benefit rate of 82% in patients selected for FGFR2 fusions, rearrangements Apr 13, 2021
Dual Targeted Tx a 'Meaningful' Option in BRAF-Mutant Glioma One-third of glioblastoma patients responded to dabrafenib-trametinib Apr 12, 2021
A Win for Nivolumab as Preoperative Therapy for Lung Cancer Pathologic CR rate 12 times higher with the addition of anti-PD-1 agent to chemo Apr 11, 2021
Immunovirotherapy Shows Promise in Pediatric High-Grade Glioma Small study showed responses in 11 of 12 patients Apr 11, 2021
Nivolumab Alone Prevails in Resected Melanoma Adding ipilimumab in adjuvant setting failed to improve relapse-free survival Apr 11, 2021
Mixed Results for Immunotherapy in Metastatic Prostate Cancer Combination trial missed response endpoint but exceeded historical results Apr 11, 2021
Practice-Changing Results in Metastatic Uveal Melanoma Bispecific T cell-engaging tebentafusp reduces survival hazard by 50% Apr 10, 2021
Add-On PI3K Inhibitor Wins in Relapsed, Indolent NHL Adding copanlisib to rituximab also doubled CR rate, with manageable toxicity Apr 10, 2021
Worse Blood Cancer Outcomes in Hispanics Diagnosis at earlier age, worse survival, especially for those on U.S.-Mexico border Jun 24, 2020
6-Week Keytruda Safe, Effective in Melanoma Schedule gets FDA approval for all adult indications Apr 30, 2020
Talzenna Misses OS Endpoint in BRCA-Positive Breast Cancer But PARP inhibitor improved patient-reported outcomes over standard therapy Apr 29, 2020
COVID-19 Mortality Spikes in Patients With Lung, Blood Cancers Those with metastatic disease also at special risk for poor outcomes Apr 28, 2020
Anti-PD-L1 Plus PARP Inhibitor Ups Response in Breast Cancer Add-on treatment superior to chemo alone, but questions remain about cost, toxicity Apr 28, 2020
Triplet Succeeds in BRAF-Mutant Melanoma Immunotherapy plus BRAF/MEK inhibition boosts PFS over targeted agents alone Apr 27, 2020
Durable Responses With Keytruda in Later-Line SCLC Plus umbralisib in marginal zone lymphoma and a next-generation TRK-targeted agent Apr 04, 2019
Genetic Variant Tied to Stroke After Brain Irradiation Tripled stroke risk in survivors of childhood cancers Apr 04, 2019
Birth Control Pills Tied to Reduced Risk of Deadly Ovarian Ca Every 5 years of use linked with 32% reduction in risk of dying within 12 months of diagnosis Apr 04, 2019
PARP Inhibitor Maintenance for Pancreatic Cancer Study takes cue from new treatment paradigm in BRCA-mutant ovarian cancer Apr 03, 2019
Reversing Melanoma Resistance to Immunotherapy HDAC inhibitor/anti-PD-1 combo active after initial anti-PD-1 failure Apr 02, 2019
Overall Survival Data in for Gilteritinib as AML Salvage Tx FLT3 Inhibitor tops chemotherapy in randomized trial Apr 01, 2019
MET Inhibitor Rescues Some Targeted Tx Failures in NSCLC Savolitinib promising in patients with MET-based resistance to EGFR inhibition Apr 01, 2019
